Omixon is a global biotechnology company that commercializes disruptive innovations specializing in targeted applications for Next Generation Sequencing (NGS). The Omixon Holotype HLA™ product combines a targeted HLA Assay and the Omixon HLA Twin™ software to deliver the most accurate high-resolution HLA genotyping available. Omixon maintains an active grant-funded research program and assists scientists and clinicians to analyze the most challenging genomic regions including HLA, KIR and ABO.
Authors: Krisztina Rigó, György Horváth, Szilveszter Juhos, Sabine Canivet, Philippe Pellet, Abdelali Boudifa, Veronique Bertrand, Ioannis Theodorou Abstract: Long reads produced by Roche 454 sequencers are used for HLA typing for quite a while. Having long reads it is easier …more
It’s already the middle of January, so before the new year steadily sets in, we’d like to have a quick look back on the route we just came, not long ago. Omixon had an amazing and very successful 2014. We launched our …more